E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Small bowel ulcers associated with iron deficiency anaemia or obscure blood loss in patients using aspirin or non-steroidal anti-inflammatory drugs |
|
E.1.1.1 | Medical condition in easily understood language |
Gut ulcers associated with low blood count or obscure internal bleeding in patients using aspirin or anti-inflammatory pain-killers |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Digestive System Diseases [C06] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10066761 |
E.1.2 | Term | Acute anaemia |
E.1.2 | System Organ Class | 10005329 - Blood and lymphatic system disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10057220 |
E.1.2 | Term | Acute post haemorrhagic anaemia |
E.1.2 | System Organ Class | 10005329 - Blood and lymphatic system disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10002034 |
E.1.2 | Term | Anaemia |
E.1.2 | System Organ Class | 10005329 - Blood and lymphatic system disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10002034 |
E.1.2 | Term | Anaemia |
E.1.2 | System Organ Class | 10005329 - Blood and lymphatic system disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10002083 |
E.1.2 | Term | Anaemia- Hypochromic microcytic picture |
E.1.2 | System Organ Class | 10005329 - Blood and lymphatic system disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10002062 |
E.1.2 | Term | Anaemia iron deficiency |
E.1.2 | System Organ Class | 10005329 - Blood and lymphatic system disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10014816 |
E.1.2 | Term | Endoscopy small intestine |
E.1.2 | System Organ Class | 10022891 - Investigations |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10014816 |
E.1.2 | Term | Endoscopy small intestine |
E.1.2 | System Organ Class | 10022891 - Investigations |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10014817 |
E.1.2 | Term | Endoscopy small intestine abnormal |
E.1.2 | System Organ Class | 10022891 - Investigations |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10014818 |
E.1.2 | Term | Endoscopy small intestine normal |
E.1.2 | System Organ Class | 10022891 - Investigations |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10041133 |
E.1.2 | Term | Small intestine ulcer |
E.1.2 | System Organ Class | 10017947 - Gastrointestinal disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10041133 |
E.1.2 | Term | Small intestine ulcer |
E.1.2 | System Organ Class | 10017947 - Gastrointestinal disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10041134 |
E.1.2 | Term | Small intestine ulcer haemorrhagic |
E.1.2 | System Organ Class | 10017947 - Gastrointestinal disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10055339 |
E.1.2 | Term | Small intestine ulcer hemorrhagic |
E.1.2 | System Organ Class | 10017947 - Gastrointestinal disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10045335 |
E.1.2 | Term | Ulcer small intestine |
E.1.2 | System Organ Class | 10017947 - Gastrointestinal disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
In cases of iron deficiency anaemia or obscure gastrointestinal bleeding: To assess the efficacy of an off-patent prostaglandin analogue, misoprostol, in healing of small bowel mucosal damage while continuing to take low-dose aspirin and/ or NSAIDs
|
|
E.2.2 | Secondary objectives of the trial |
To assess the change in haemoglobin level following the intake of misoprostol in patients with iron deficiency anaemia/ obscure blood loss and small bowel damage induced by low-dose aspirin or NSAIDs |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Inclusion criteria • Obscure occult gastrointestinal bleeding: • Iron deficiency anaemia (ferritin <100 ug/l, hemoglobin [Hb] 7–12 g/dl [female] or 7–13 g/dl [male]) • Normal upper endoscopy and colonoscopy • Taking low-dose aspirin (75-325m/ day) or NSAIDs • Drop in haemoglobin, > 2gm/dl, over two measurements taken within 3 months of the screening visit, in the absence of potential or actively bleeding lesion detectable on upper endoscopy or colonoscopy.
|
|
E.4 | Principal exclusion criteria |
Exclusion criteria Any of the following is regarded as criterion for exclusion from the study:
1. Systemic disease that is unstable at the time of randomisation [unstable vital signs (pulse, blood pressure, respiratory rate, temperature, etc); ongoing non-gastrointestinal investigations; frequent (more than once/ week) modifications to treatment] 2. Upper gastrointestinal lesions: oesophageal varices; erosive oesophagitis; oesophageal stricture; oesophageal or gastric neoplasms; pyloric stenosis; peptic ulcers; vascular malformations. 3. Colonic disorders: neoplasms or adenomatous polyps; inflammatory bowel disease; vascular malformations; actively bleeding diverticular disease 4. Pregnancy, lactation, or women of child-bearing potential not using two contraceptive methods, one of which must be highly effective, or planning pregnancy. “Women Not of Childbearing Potential” are defined as those women who are postmenopausal or permanently sterilised (e.g. tubal occlusion, hysterectomy, bilateral salpingectomy). “Women of Childbearing Potential” are defined as any female who have experienced menarche and do not meet the criteria for “Women Not of Childbearing Potential”. “ Preferred Highly Effective Contraceptive Methods" are those with lower use dependency and include implants, injectables, and some intrauterine devices (IUDs). Combined oral contraceptives, sexual abstinence or vasectomised partner (provided that partner is sole sexual partner and that surgical success has been confirmed in the vasectomised partner) may also be used. Other contraception methods such as barrier contraception with our without spermicide may be used in combination with a highly effective method of contraception. 5. Hypotension: systolic blood pressure <100-mm Hg. 6. History of oesophageal, gastric or duodenal surgery, excluding simple closure of an ulcer or vagotomy. 7. Current or historical evidence of any of the following diseases: a. Zollinger-Ellison syndrome. b. Primary oesophageal motility disorder(s) ie, achalasia, scleroderma, primary oesophageal spasm. c. Malabsorption. 8. Significant cardiovascular, pulmonary, renal, pancreatic or liver disease as judged by the investigator to interfere with the evaluation of the study. 9. Unstable diabetes mellitus (stable diabetes controlled by diet, oral agents or insulin is not an exclusion criterion). 10. Cerebrovascular disease such as cerebral ischaemia, infarction, haemorrhage or embolus as judged by the investigator to interfere with the evaluation of the study. 11. Suspected or confirmed current malignancy, except minor superficial skin disease. 12. Use of any other investigational compound or participation in another clinical trial within the 90 days prior to start of study medication. 13. Need for continuous concomitant therapy with: a. Warfarin b. High dose steroids (more than 7.5 mg of prednisolone or its equivalent daily). c. Cytotoxic drugs with the exception of methotrexate in patients with arthritis 14. Alcohol and/or drug abuse or any condition associated with poor compliance including expected non-cooperation, as judged by the investigator. 15. Previous participation in this study. 16. Contraindications to study drugs, e.g., known or suspected allergy to misoprostol
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Full healing of small bowel mucosal ulcers or erosions [in patients with iron deficiency anaemia or obscure blood loss, using misoprostol and while continuing on their aspirin or NSAIDs] |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Eight weeks post randomisation |
|
E.5.2 | Secondary end point(s) |
(i) Change in blood haemoglobin level (ii) Change in the numbers of mucosal erosions
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
(i) Change in blood haemoglobin level: 4 and 8 weeks post randomisation
(ii) Change in the numbers of mucosal erosions: 8 weeks post randomisation |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 11 |
E.8.9.2 | In all countries concerned by the trial days | 30 |